Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double‐Blind, Randomized, Placebo‐Controlled Trial
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background: The glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide may be beneficial in the regression of diabetic cardiomyopathy. South Asian ethnic groups in particular are at risk of developing type 2 diabetes. Purpose: To assess the effects of liraglutide on left ventricular (LV) diastolic and systolic function in South Asian type 2 diabetes patients. Study Type: Prospective, double‐blind, randomized, placebo‐controlled trial. Population: Forty‐seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26‐week treatment with liraglutide (1.8 mg/day) or placebo. Field Strength/Sequence: 3T (balanced steady‐state free precession cine MRI, 2D and 4D velocity‐encoded MRI, 1 H‐MRS, T 1 mapping). Assessment: Primary endpoints were changes in LV diastolic function (early deceleration peak [Edec], ratio of early and late peak filling rate [E/A], estimated LV filling pressure [E/Ea]) and LV systolic function (ejection fraction). Secondary endpoints were changes in aortic stiffness (aortic pulse wave velocity [PWV]), myocardial steatosis (myocardial triglyceride content), and diffuse fibrosis (extracellular volume [ECV]). Statistical Tests: Data were analyzed according to intention‐to‐treat. Between‐group differences were reported as mean (95% confidence interval [CI]) and were assessed using analysis of covariance (ANCOVA). Results: Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s 2 × 10‐3 (–0.3;0.6)), E/A (–0.09 (–0.23;0.05)), E/Ea (+0.1 (–1.2;1.3)) and ejection fraction (0% (–3;2)), but decreased stroke volume (–9 mL (–14;–5)) and increased heart rate (+10 bpm (4;15)). Aortic PWV (+0.5 m/s (–0.6;1.6)), myocardial triglyceride content (+0.21% (–0.09;0.51)), and ECV (–0.2% (–1.4;1.0)) were unaltered. Data Conclusion: Liraglutide did not affect LV diastolic and systolic function, aortic stiffness, myocardial triglyceride content, or extracellular volume in Dutch South Asian type 2 diabetes patients with or without coronary artery disease. Level of Evidence: 1 Technical Efficacy Stage: 4 J. Magn. Reson. Imaging 2020;51:1679–1688.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“Conversely, the previously reported reduced cardiovascular mortality rate in response to liraglutide among patients with type 2 diabetes and high cardiovascular risk is probably primarily related to slowed progression of atherosclerosis.(3,41) Following the results from recent cardiovascular outcome trials,(3,4) SGLT2…”
BackgroundResultZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · cited 1×
“Similar reductions in cardiovascular mortality have been reported in response to treatment with the GLP-1 receptor agonists semaglutide and dulaglutide.(4) However, it is largely unknown whether liraglutide in the management of type 2 diabetes is advantageous for heart function in asymptomatic diastolic dysfunction.”
ResultMargulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 8×
“Furthermore, it has been suggested that the cardioprotective effects of native GLP-1 as described in earlier studies may be related to actions of degradation products of GLP-1, which are not produced by GLP-1 analogs.(2) We hypothesized that liraglutide may reverse diabetic cardiomyopathy, partly as a result of its in…”
BackgroundResultInfluential6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · cited 1×
“Conversely, the previously reported reduced cardiovascular mortality rate in response to liraglutide among patients with type 2 diabetes and high cardiovascular risk is probably primarily related to slowed progression of atherosclerosis.(3,41) Following the results from recent cardiovascular outcome trials,(3,4) SGLT2…”
Result10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy
Marwick, T. H., Ritchie, R., Shaw, J. E., & Kaye, D. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.019 · Cited by 365
GLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262 · cited 1×
“However, attenuation of myocardial steatosis by treatment with GLP-1 receptor agonists in type 2 diabetes has not been confirmed in human studies.(36) In a recent double-blind randomized controlled trial on the effect of liraglutide on cardiac function in European type 2 diabetes patients,(37) liraglutide decreased th…”
BackgroundNoyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259
Empagliflozin directly improves diastolic function in human heart failure
Pabel, S., Wagner, S., Bollenberg, H., Bengel, P., Kovács, Á., Schach, C., Tirilomis, P., Mustroph, J., Renner, A., Gummert, J., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1328 · Cited by 224 · cited 1×
“In contrast, recent studies have indicated that the sodium-glucose co-transporter 2 (SGLT2) inhibitors empagliflozin, canagliflozin, and dapagliflozin have a benefit on the incidence of heart failure,(4) potentially because of direct improvement of myocardial relaxation in addition to diuretic effects.(40) Conversely,…”
ResultAdipose Tissue Metabolites and Insulin Resistance in Nondiabetic Asian Indian Men
Abate, N., Chandalia, M., Snell, P. G., & Grundy, S. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031843 · Cited by 201 · cited 1×
“In addition, adipocytes may be dysfunctional, as reflected by the increased release of free fatty acids, adipokines, and proinflammatory cytokines among South Asian individuals.(13,14) Previously, it has been demonstrated that hyperglycemia is more detrimental for cardiac function in South Asians than in Europeans.”
BackgroundKoska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174
Lovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168
Lambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0646-z · Cited by 146
Bizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0857-6 · Cited by 137 · cited 1×
“A previous study reported a reduced LV filling pressure after liraglutide therapy in a European cohort of type 2 diabetes patients without ischemic heart disease, who were predominantly men, with a shorter diabetes duration, and less use of insulin as compared with the South Asian type 2 diabetes patients in the prese…”
Resultvan Eyk, H. J., Paiman, E. H. M., Bizino, M. B., de Heer, P., Geelhoed-Duijvestijn, P. H., Kharagjitsingh, A. V., Smit, J. W. A., Lamb, H. J., Rensen, P. C. N., & Jazet, I. M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0890-5 · Cited by 90
Self-citationNakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., & Nakamoto, T. (2016) · Diabetes Care · doi:10.2337/dc15-1437 · Cited by 77
Cited by
Bizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0857-6 · Cited by 137
Vernstrøm, L., Gullaksen, S., Sørensen, S. S., Funck, K. L., Laugesen, E., & Poulsen, P. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15464 · Cited by 30
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22
Metadata
- Authors
- Paiman, E. H. M., van Eyk, H. J., van Aalst, M. M. A., Bizino, M. B., van der Geest, R. J., Westenberg, J. J. M., Geelhoed‐Duijvestijn, P. H., Kharagjitsingh, A. V., Rensen, P. C. N., Smit, J. W. A., Jazet, I. M., & Lamb, H. J.
- Venue
- Journal of Magnetic Resonance Imaging
- Publisher
- Wiley
- Published
- 2019-12-04
- Volume
- 51
- Issue
- 6
- Pages
- 1679-1688
- ISSN
- 1053-1807 (ISSN-L)
- 1522-2586
- OpenAlex
- W2992821646
- Cited by
- 41
- References
- 21
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.